Core Viewpoint - A securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. for allegedly making false or misleading statements in its IPO prospectus, particularly regarding adverse clinical trial data [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Kyverna common stock during its IPO on February 8, 2024, with a lead plaintiff deadline set for February 7, 2025 [1]. - The complaint claims that Kyverna's prospectus contained materially false and misleading statements about the company's business and operations, specifically omitting adverse data from a clinical trial at the time of the IPO [2]. Group 2: Lead Plaintiff Process - Investors can seek to be appointed as a lead plaintiff representative by February 7, 2025, or may choose to remain absent from the class [3]. - The lead plaintiff will represent all class members and select counsel to direct the litigation, with the ability to recover not affected by the decision to serve as lead plaintiff [3]. Group 3: Firm Information - Kessler Topaz Meltzer & Check, LLP is encouraging Kyverna investors who have experienced significant losses to contact them for more information [4]. - The firm has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [5].
KYTX Announcement: Contact Kessler Topaz Meltzer & Check, LLP About the Securities Fraud Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc.